

# Roberto Latagliata

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6100344/publications.pdf>

Version: 2024-02-01

351  
papers

6,794  
citations

61857

43  
h-index

91712

69  
g-index

356  
all docs

356  
docs citations

356  
times ranked

5972  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.	1.2	20
2	Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients. <i>Supportive Care in Cancer</i> , 2022, 30, 4303-4314.	1.0	3
3	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-OL study. <i>British Journal of Haematology</i> , 2022, 197, 190-200.	1.2	7
4	Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical "Biological Entity?". <i>Journal of Clinical Medicine</i> , 2022, 11, 2596.	1.0	0
5	Very late acute myeloid leukemia relapse: clinical features, treatment and outcome. <i>Leukemia and Lymphoma</i> , 2021, 62, 1022-1025.	0.6	2
6	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e328-e333.	0.2	0
7	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368.	1.2	19
8	Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up. <i>Leukemia and Lymphoma</i> , 2021, 62, 1026-1027.	0.6	4
9	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4.	2.8	41
10	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. <i>Hematological Oncology</i> , 2021, 39, 409-418.	0.8	9
11	Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2261-2266.	0.6	0
12	Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine kinase inhibitors. <i>Hematological Oncology</i> , 2021, 39, 401-408.	0.8	8
13	Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2021, 100, 1213-1219.	0.8	4
14	New dead/H-box helicase gene (ddx41) mutation in an Italian family with recurrent leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2280-2283.	0.6	6
15	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021, 127, 2657-2665.	2.0	14
16	Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. <i>Acta Oncologica</i> , 2021, 60, 1520-1526.	0.8	2
17	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. <i>Acta Oncologica</i> , 2021, 60, 1527-1533.	0.8	2
18	From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox. <i>Frontiers in Oncology</i> , 2021, 11, 752192.	1.3	7

#	ARTICLE	IF	CITATIONS
19	Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality. <i>American Journal of Blood Research</i> , 2021, 11, 417-426.	0.6	0
20	Nursing Management of Frail Patients with Hematologic Malignancies during COVID-19 Pandemia in the Viterbo Domiciliary Care Unit: Data Analysis from March 2020 to March 2021. <i>Blood</i> , 2021, 138, 3022-3022.	0.6	0
21	Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021, 138, 1487-1487.	0.6	0
22	Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021, 138, 3617-3617.	0.6	1
23	Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1486-1486.	0.6	0
24	Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Polycythemia Vera Resistant/Intolerant to Hydroxyurea. <i>Blood</i> , 2021, 138, 2581-2581.	0.6	1
25	NGS Evaluation of the Ego1-MDS Trial: Preliminary Analysis of Eltrombopag for Thrombocytopenia of Low-Risk MDS. <i>Blood</i> , 2021, 138, 1516-1516.	0.6	0
26	Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients. <i>Supportive Care in Cancer</i> , 2020, 28, 4193-4199.	1.0	20
27	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	2.0	106
28	Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. <i>Hematological Oncology</i> , 2020, 38, 189-196.	0.8	6
29	SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. <i>HemaSphere</i> , 2020, 4, e483.	1.2	7
30	Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance. <i>Leukemia and Lymphoma</i> , 2020, 61, 3476-3483.	0.6	2
31	Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. <i>Annals of Hematology</i> , 2020, 99, 2405-2416.	0.8	11
32	Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia. <i>European Journal of Haematology</i> , 2020, 105, 286-291.	1.1	2
33	Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2020, 99, 2773-2777.	0.8	2
34	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. <i>Leukemia</i> , 2020, 34, 2260-2261.	3.3	57
35	PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 426-430.	1.0	11
36	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020, 38, 372-380.	0.8	15

#	ARTICLE	IF	CITATIONS
37	Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the Ph1-negative Myeloproliferative Neoplasms Latium Group. European Journal of Haematology, 2020, 105, 335-343.	1.1	8
38	Hematologic alterations and early mortality in a cohort of HIV positive African patients. PLoS ONE, 2020, 15, e0242068.	1.1	5
39	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. Annals of Hematology, 2019, 98, 2329-2338.	0.8	17
40	Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy. Hematological Oncology, 2019, 37, 447-455.	0.8	25
41	Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome. Hematological Oncology, 2019, 37, 652-654.	0.8	17
42	Incidence of Clinically Significant ( $\geq 10$ g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib. Oncology Research and Treatment, 2019, 42, 660-664.	0.8	2
43	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. Annals of Hematology, 2019, 98, 1933-1936.	0.8	5
44	Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. Annals of Hematology, 2019, 98, 1919-1925.	0.8	8
45	Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life. Annals of Hematology, 2019, 98, 1891-1904.	0.8	10
46	Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. Hematological Oncology, 2019, 37, 291-295.	0.8	14
47	Management and outcome of 11 pregnancies in women with polycythemia vera. Leukemia Research, 2019, 81, 25-26.	0.4	2
48	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. Hematological Oncology, 2019, 37, 418-423.	0.8	3
49	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica, 2019, 104, 1589-1596.	1.7	58
50	Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?. Leukemia Research, 2019, 76, 65-69.	0.4	8
51	Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. Blood Reviews, 2019, 34, 16-25.	2.8	15
52	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. Annals of Hematology, 2019, 98, 889-896.	0.8	10
53	Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial. Blood, 2019, 134, 3000-3000.	0.6	7
54	Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kinase Inhibitors. Blood, 2019, 134, 1649-1649.	0.6	7

#	ARTICLE	IF	CITATIONS
55	Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. <i>Blood</i> , 2019, 134, 839-839.	0.6	2
56	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. <i>Blood</i> , 2019, 134, 4166-4166.	0.6	0
57	Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement. <i>Blood</i> , 2019, 134, 3010-3010.	0.6	0
58	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019, 134, 4184-4184.	0.6	1
59	Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019, 134, 4174-4174.	0.6	2
60	Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. <i>Blood</i> , 2019, 134, 3845-3845.	0.6	1
61	Iron toxicity – Its effect on the bone marrow. <i>Blood Reviews</i> , 2018, 32, 473-479.	2.8	46
62	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	0.8	46
63	Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. <i>Leukemia Research</i> , 2018, 69, 18-23.	0.4	2
64	Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib. <i>British Journal of Haematology</i> , 2018, 181, 275-278.	1.2	3
65	Comparison of <i>JAK2</i> <sup>V617F</sup> -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology. <i>Hematological Oncology</i> , 2018, 36, 269-275.	0.8	11
66	Efficacy and safety of ruxolitinib in intermediate-IPSS risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018, 36, 285-290.	0.8	29
67	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , 2018, 97, 95-100.	0.8	32
68	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018, 74, 86-88.	0.4	23
69	Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events. <i>Annals of Hematology</i> , 2018, 97, 1803-1808.	0.8	18
70	Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2018, 97, 1797-1802.	0.8	20
71	The IPSS-R has prognostic impact in untreated patients with MDS del(5q). <i>Leukemia Research</i> , 2018, 72, 27-33.	0.4	3
72	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018, 183, 35-46.	1.2	7

#	ARTICLE	IF	CITATIONS
73	Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2018, 71, 89-91.	0.4	2
74	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018, 55, 248-255.	1.8	24
75	Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. <i>European Journal of Haematology</i> , 2018, 101, 578-584.	1.1	3
76	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018, 132, 4277-4277.	0.6	11
77	Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. <i>Oncotarget</i> , 2018, 9, 7534-7540.	0.8	19
78	Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?. <i>Blood</i> , 2018, 132, 1746-1746.	0.6	0
79	Presentation and Outcome of 199 Patients with 2016 WHO Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018, 132, 3052-3052.	0.6	0
80	Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice. <i>Blood</i> , 2018, 132, 5518-5518.	0.6	0
81	Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice. <i>Blood</i> , 2018, 132, 1741-1741.	0.6	0
82	Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?. <i>Blood</i> , 2018, 132, 5516-5516.	0.6	0
83	Frontline Treatment with Dasatinib in Very Elderly Patients (> 75 Years) with Chronic Myeloid Leukemia: Is It Feasible?. <i>Blood</i> , 2018, 132, 5438-5438.	0.6	0
84	Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI). <i>Blood</i> , 2018, 132, 4312-4312.	0.6	0
85	Management and Outcome of 11 Pregnancies in Women with Polycythemia Vera. <i>Blood</i> , 2018, 132, 5471-5471.	0.6	0
86	Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 3021-3021.	0.6	0
87	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of WHO 2001 Versus WHO 2008/2016 Criteria in a Large Single Center Cohort. <i>Blood</i> , 2018, 132, 5464-5464.	0.6	0
88	Impact of exclusion criteria for the DASISION and ENESTnd trials in the frontline treatment of a real-life patient population with chronic myeloid leukaemia. <i>Hematological Oncology</i> , 2017, 35, 232-236.	0.8	13
89	Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. <i>Lancet Haematology</i> , 2017, 4, e127-e136.	2.2	132
90	Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. <i>Cancer Medicine</i> , 2017, 6, 1233-1239.	1.3	9

#	ARTICLE	IF	CITATIONS
91	Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life. American Journal of Hematology, 2017, 92, E668-E670.	2.0	7
92	The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. American Journal of Hematology, 2017, 92, E661-E664.	2.0	14
93	ITACA: A new validated international erythropoietic stimulating agent response score that further refines the predictive power of previous scoring systems. American Journal of Hematology, 2017, 92, 1037-1046.	2.0	20
94	High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. Thrombosis Research, 2017, 156, 168-171.	0.8	9
95	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. American Journal of Hematology, 2017, 92, 37-41.	2.0	62
96	Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia. Hematological Oncology, 2017, 35, 804-809.	0.8	5
97	Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. Annals of Hematology, 2017, 96, 387-391.	0.8	14
98	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget, 2017, 8, 79073-79086.	0.8	63
99	A POPULATION-BASED STUDY ON MYELOYDYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017046.	0.5	3
100	Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase. European Journal of Haematology, 2016, 96, 643-649.	1.1	19
101	Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. European Journal of Haematology, 2016, 96, 344-351.	1.1	31
102	Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a Gruppo Romano Mielodisplasie (GROM) multicenter study. Annals of Hematology, 2016, 95, 1059-1065.	0.8	7
103	The risk of infections in patients with myelodysplastic syndromes in 2016. Expert Review of Hematology, 2016, 9, 607-614.	1.0	13
104	Frontline Dasatinib Treatment in a Real-Life Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. Neoplasia, 2016, 18, 536-540.	2.3	24
105	Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients. American Journal of Hematology, 2016, 91, 318-321.	2.0	28
106	Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response. Leukemia and Lymphoma, 2016, 57, 99-102.	0.6	13
107	JAK2V617F allele burden $\geq 50\%$ is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy. Leukemia, 2016, 30, 1772-1775.	3.3	50
108	Dasatinib first-line: Multicentric Italian experience outside clinical trials. Leukemia Research, 2016, 40, 24-29.	0.4	6

#	ARTICLE	IF	CITATIONS
109	Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. <i>Blood</i> , 2016, 128, 1128-1128.	0.6	4
110	Incidence of Severe ( $\geq 10\text{g/dl}$ ) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy. <i>Blood</i> , 2016, 128, 1903-1903.	0.6	1
111	Incidence of Early Thrombosis in Myeloproliferative Neoplasms (MPN): A Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN. <i>Blood</i> , 2016, 128, 1951-1951.	0.6	3
112	Efficacy and Safety of Ruxolitinib in Elderly Patients ( $\geq 75$ years) with Myelofibrosis. <i>Blood</i> , 2016, 128, 4251-4251.	0.6	2
113	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016, 7, 80083-80090.	0.8	24
114	Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis. <i>Blood</i> , 2016, 128, 5464-5464.	0.6	0
115	Latum (Italy) Epidemiology of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs) from 2011 to 2015: A Prospective Analysis from Gruppo Laziale of Ph Negative MPN. <i>Blood</i> , 2016, 128, 5473-5473.	0.6	0
116	Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment. <i>Blood</i> , 2016, 128, 5544-5544.	0.6	1
117	Essential Thrombocythemia: A Comparison of Overall and Thrombosis Free Survival in Two Discrete Periods of the First Decade of 2000. a Retrospective Analysis. <i>Blood</i> , 2016, 128, 5469-5469.	0.6	0
118	Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2016, 128, 5465-5465.	0.6	1
119	Young CML Patients Treated Frontline with Imatinib or Second Generation TKIs: Clinical Characteristics and Outcome. <i>Blood</i> , 2016, 128, 3078-3078.	0.6	0
120	Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib. <i>American Journal of Hematology</i> , 2015, 90, 105-108.	2.0	10
121	Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with <i>ATRA</i> and chemotherapy. <i>American Journal of Hematology</i> , 2015, 90, E181-2.	2.0	2
122	Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?. <i>Hematological Oncology</i> , 2015, 33, 48-51.	0.8	3
123	Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. <i>Leukemia Research</i> , 2015, 39, 801-804.	0.4	25
124	Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC). <i>Supportive Care in Cancer</i> , 2015, 23, 3289-3295.	1.0	39
125	Early lenalidomide treatment for low and intermediate-risk International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence. <i>Cancer Medicine</i> , 2015, 4, 1789-1797.	1.3	18
126	Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront. <i>Leukemia and Lymphoma</i> , 2015, 56, 2206-2207.	0.6	6



#	ARTICLE	IF	CITATIONS
127	Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age. <i>Annals of Hematology</i> , 2015, 94, 195-200.	0.8	15
128	Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. <i>Leukemia Research</i> , 2015, 39, 314-317.	0.4	11
129	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	0.6	72
130	Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients. <i>American Journal of Hematology</i> , 2015, 90, E95-E96.	2.0	0
131	Deferasirox chelation therapy in patients with transfusion-dependent <scp>MDS</scp>: a "real-world" report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata. <i>European Journal of Haematology</i> , 2015, 95, 52-56.	1.1	22
132	Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. <i>Leukemia</i> , 2015, 29, 1344-1349.	3.3	62
133	Erythropoietin treatment in patients with myelodysplastic syndromes and type 2 diabetes. <i>Diabetes</i> , 2015, 7, 493-496.	0.8	0
134	Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients. <i>Blood</i> , 2015, 126, 1606-1606.	0.6	2
135	Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?. <i>Blood</i> , 2015, 126, 4038-4038.	0.6	1
136	Cost Description on a Cohort of 659 Patients with Adult MDS Included into the Italian Lazio Region Registry (the GROM-L). <i>Blood</i> , 2015, 126, 5237-5237.	0.6	1
137	Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial. <i>Blood</i> , 2015, 126, 91-91.	0.6	7
138	JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome. <i>Blood</i> , 2015, 126, 1614-1614.	0.6	0
139	The Platelet COUNT at Diagnosis of Essential Thrombocythemia Is a Prognostic Factor for Thrombosis-Free Survival: Retrospective Analysis on 1201 Patients. <i>Blood</i> , 2015, 126, 2815-2815.	0.6	0
140	Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response. <i>Blood</i> , 2015, 126, 1582-1582.	0.6	0
141	Are ET and PV Patients Two Similar Populations As Concern Thrombotic Risk Factors?. <i>Blood</i> , 2015, 126, 2811-2811.	0.6	4
142	Application of the International Prognostic Score of Thrombosis for Essential Thrombocythemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms. <i>Blood</i> , 2015, 126, 2821-2821.	0.6	1
143	Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline. <i>Blood</i> , 2015, 126, 1598-1598.	0.6	0
144	Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML). <i>BioDrugs</i> , 2014, 28, 17-26.	2.2	24

#	ARTICLE	IF	CITATIONS
145	Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study. <i>Annals of Hematology</i> , 2014, 93, 1413-1420.	0.8	7
146	Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. <i>American Journal of Hematology</i> , 2014, 89, 565-565.	2.0	2
147	Thrombosis and survival in essential thrombocythemia: A regional study of 1,144 patients. <i>American Journal of Hematology</i> , 2014, 89, 542-546.	2.0	33
148	Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. <i>Leukemia Research</i> , 2014, 38, 1173-1176.	0.4	30
149	Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells. <i>Annals of Hematology</i> , 2014, 93, 1819-1823.	0.8	23
150	Pregnancy in acute promyelocytic leukaemia after frontline therapy with arsenic trioxide and all-trans retinoic acid. <i>British Journal of Haematology</i> , 2014, 167, 428-430.	1.2	6
151	Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. <i>Leukemia Research</i> , 2014, 38, 194-197.	0.4	23
152	Prognostic Factors for Thrombosis-Free Survival and Overall Survival in Polycythemia Vera: A Retrospective Analysis of 623 Patients Series with Long Follow-up. <i>Blood</i> , 2014, 124, 1855-1855.	0.6	0
153	Real-life Frontline Dasatinib Treatment in Unselected Elderly Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2014, 124, 5530-5530.	0.6	0
154	The Experience of Gruppo Laziale for the Study of Ph-, Chronic Myeloproliferative Syndromes in the Treatment of Myeloproliferative Neoplasms in Blastoid Phase with Azacitidine. <i>Blood</i> , 2014, 124, 3164-3164.	0.6	1
155	Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 3687-3687.	0.6	0
156	Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry. <i>Blood</i> , 2014, 124, 3265-3265.	0.6	0
157	Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 1063-1063.	0.6	0
158	Mutations and Long-Term Outcome of 217 Young Patients with Essential Thrombocythemia or Early Primary Myelofibrosis. <i>Blood</i> , 2014, 124, 3190-3190.	0.6	0
159	Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic Aspects. <i>Blood</i> , 2014, 124, 5326-5326.	0.6	0
160	Hematological Improvement during Deferasirox Treatment in Patients with Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2014, 124, 3189-3189.	0.6	0
161	Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. <i>Hematological Oncology</i> , 2013, 31, 103-109.	0.8	59
162	Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study. <i>Drugs and Aging</i> , 2013, 30, 629-637.	1.3	36

#	ARTICLE	IF	CITATIONS
163	Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. <i>Annals of Hematology</i> , 2013, 92, 179-183.	0.8	12
164	Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. <i>Annals of Hematology</i> , 2013, 92, 25-32.	0.8	23
165	Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. <i>Leukemia and Lymphoma</i> , 2013, 54, 2458-2465.	0.6	29
166	Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib. <i>Cancer Letters</i> , 2013, 333, 32-35.	3.2	19
167	Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17). <i>Journal of Clinical Oncology</i> , 2013, 31, 4424-4430.	0.8	78
168	Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols. <i>Leukemia Research</i> , 2013, 37, 383-385.	0.4	3
169	MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013045.	0.5	6
170	Complete Clearance of Ph+ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia. <i>Acta Haematologica</i> , 2013, 129, 126-134.	0.7	5
171	Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. <i>New England Journal of Medicine</i> , 2013, 368, 22-33.	13.9	664
172	Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database. <i>Journal of Clinical Oncology</i> , 2013, 31, 2671-2677.	0.8	121
173	FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis. <i>Haematologica</i> , 2013, 98, e161-e163.	1.7	49
174	Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a "Real-life" Patient Population With Chronic Myelogenous Leukemia?. <i>Blood</i> , 2013, 122, 4002-4002.	0.6	1
175	FLT3-ITD Internal Tandem Duplication Confers Poor Prognosis In Patients With Acute Promyelocytic Leukemia Treated With The AIDA Protocols. Long-Term Follow-Up Analysis. <i>Blood</i> , 2013, 122, 1336-1336.	0.6	0
176	Real-Life Efficacy Of Azacitidine In Myelodysplastic Syndromes According To IPSS Cytogenetic Profile. <i>Blood</i> , 2013, 122, 5229-5229.	0.6	0
177	Deferasirox In The Treatment Of Iron Overload During Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2013, 122, 1594-1594.	0.6	0
178	Prognostic Factors Associated To Achievement Of Complete Or Partial Response In MDS Patients Treated With Azacitidine Outside Clinical Trials. <i>Blood</i> , 2013, 122, 5203-5203.	0.6	0
179	Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. <i>Blood</i> , 2012, 119, 49-54.	0.6	63
180	Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. <i>Haematologica</i> , 2012, 97, 560-567.	1.7	61

#	ARTICLE	IF	CITATIONS
181	The EUTOS score identifies chronic myeloid leukaemia patients with poor prognosis treated with imatinib first or second line. <i>Leukemia Research</i> , 2012, 36, e209-e210.	0.4	19
182	Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience. <i>Leukemia and Lymphoma</i> , 2012, 53, 2439-2443.	0.6	6
183	Deferasirox treatment for myelodysplastic syndromes: overall-life efficacy and safety in a single-institution patient population. <i>Annals of Hematology</i> , 2012, 91, 1345-1349.	0.8	31
184	Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Cancer</i> , 2012, 118, 404-409.	2.0	40
185	Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. <i>Annals of Hematology</i> , 2012, 91, 309-310.	0.8	4
186	How Epidemiology of Polycythemia Vera Has Changed in the Last 10 Years: Results From the Whole Prospective Cohort of Patients in Cyto-PV Trial As Compared with Eclap Prospective Cohort. <i>Blood</i> , 2012, 120, 1748-1748.	0.6	1
187	A Large-Scale Trial Testing the Intensity of Cytoreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (CYTO-PV trial). <i>Blood</i> , 2012, 120, 4-4.	0.6	3
188	Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS). <i>Blood</i> , 2012, 120, 923-923.	0.6	10
189	The Role of Previous Thrombotic Events in Patients with Essential Thrombocythemia: The Earlier the Worse?. <i>Blood</i> , 2012, 120, 5062-5062.	0.6	0
190	Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom Experience. <i>Blood</i> , 2012, 120, 4958-4958.	0.6	0
191	Delayed Cytogenetic Response and Reduced Rate of Major Molecular Response Associated to Increased Body Mass Index At Baseline in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib. <i>Blood</i> , 2012, 120, 2784-2784.	0.6	0
192	Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib. <i>Blood</i> , 2012, 120, 3769-3769.	0.6	0
193	Long-Term Follow-up of Chronic Phase Chronic Myeloid Leukemia Patients Who Failed Interferon Alpha and Switched to Imatinib. <i>Blood</i> , 2012, 120, 3742-3742.	0.6	0
194	AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. <i>Blood</i> , 2011, 117, 4716-4725.	0.6	173
195	Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia. <i>Haematologica</i> , 2011, 96, 1390-1391.	1.7	20
196	Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. <i>Haematologica</i> , 2011, 96, 1457-1461.	1.7	58
197	Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a "grey zone" at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention. <i>British Journal of Haematology</i> , 2011, 152, 119-121.	1.2	9
198	GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. <i>British Journal of Haematology</i> , 2011, 154, 564-568.	1.2	22

#	ARTICLE	IF	CITATIONS
199	Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. <i>Leukemia Research</i> , 2011, 35, 1164-1169.	0.4	28
200	Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. <i>Leukemia Research</i> , 2011, 35, 159-162.	0.4	36
201	Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. <i>Leukemia Research</i> , 2011, 35, 504-507.	0.4	12
202	Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide. <i>Leukemia Research</i> , 2011, 35, e69-e70.	0.4	2
203	Familial occurrence of myelodysplastic syndrome with del(5q). <i>Leukemia and Lymphoma</i> , 2011, 52, 1143-1145.	0.6	0
204	Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. <i>Haematologica</i> , 2011, 96, 696-702.	1.7	64
205	Unexpected Erythroid and Cytogenetic Responses After Discontinuation of a Short Course of Lenalidomide As a Result of Severe Skin Rash in a Patient With 5q Syndrome. <i>Journal of Clinical Oncology</i> , 2011, 29, e402-e403.	0.8	6
206	Management of the 2009 A/H1N1 Influenza Pandemic in Patients with Hematologic Diseases: A Prospective Experience at an Italian Center. <i>Acta Haematologica</i> , 2011, 126, 1-7.	0.7	7
207	Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?. <i>Blood</i> , 2011, 118, 2770-2770.	0.6	1
208	Treatment with Erythropoietic Stimulating Agents in IPSS Lower Risk MDS: Outcome Comparison Between 5q- and Non 5q- MDS Cases. <i>Blood</i> , 2011, 118, 2799-2799.	0.6	1
209	Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,. <i>Blood</i> , 2011, 118, 3783-3783.	0.6	2
210	MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,. <i>Blood</i> , 2011, 118, 3793-3793.	0.6	1
211	Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment. <i>Blood</i> , 2011, 118, 4445-4445.	0.6	0
212	Clinical Follow-up of Patients with Myeloproliferative Neoplasms Presenting Skin Ulcers During Treatment with Hydroxyurea. <i>Blood</i> , 2011, 118, 5157-5157.	0.6	0
213	Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative Patients. <i>Blood</i> , 2011, 118, 5172-5172.	0.6	0
214	APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS. <i>Blood</i> , 2011, 118, 1686-1686.	0.6	0
215	Risk Factors for Thrombosis Vary According to Age in Patients with Essential Thrombocythemia: a Retrospective Analysis of 1090 Patients from the "Gruppo Laziale SMPC Ph Negative". <i>Blood</i> , 2011, 118, 3854-3854.	0.6	0
216	Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elderly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival. <i>Blood</i> , 2011, 118, 2751-2751.	0.6	1

#	ARTICLE	IF	CITATIONS
217	Increased Body Mass Index Correlates with Higher Risk of Disease Relapse and Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia Treated with Aida Protocols. <i>Blood</i> , 2011, 118, 4866-4866.	0.6	0
218	Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. <i>Hematological Oncology</i> , 2010, 28, 89-92.	0.8	12
219	Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. <i>Haematologica</i> , 2010, 95, 853-854.	1.7	49
220	Changes in <i>RPS14</i> expression levels during lenalidomide treatment in Low- and Intermediate- risk myelodysplastic syndromes with chromosome 5q deletion. <i>European Journal of Haematology</i> , 2010, 85, 231-235.	1.1	25
221	Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up. <i>American Journal of Hematology</i> , 2010, 85, 375-377.	2.0	10
222	Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. <i>Leukemia Research</i> , 2010, 34, 143-147.	0.4	37
223	Real-life results of front-line treatment with Imatinib in older patients (>65 years) with newly diagnosed chronic myelogenous leukemia. <i>Leukemia Research</i> , 2010, 34, 1472-1475.	0.4	53
224	Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients. <i>Leukemia and Lymphoma</i> , 2010, 51, 783-788.	0.6	17
225	Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. <i>Leukemia and Lymphoma</i> , 2010, 51, 1007-1014.	0.6	36
226	Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML. <i>Blood</i> , 2010, 116, 2293-2293.	0.6	2
227	Increases In Mirna-145 and Mirna-146a Expression In Patients with IPSS Lower-Risk Myelodysplastic Syndromes and Del(5q) Treated with Lenalidomide.. <i>Blood</i> , 2010, 116, 3631-3631.	0.6	1
228	Myelodysplastic Syndrome Patients Younger Than 50 Years: Epidemiological Data and Clinical Features. <i>Blood</i> , 2010, 116, 4976-4976.	0.6	0
229	Retrospective Application of European LeukemiaNet Provisional Criteria for Second-Generation TKI Chronic Myeloid Leukemia. <i>Blood</i> , 2010, 116, 2270-2270.	0.6	0
230	Hammersmith Score Is Able to Identify Chronic Myeloid Leukemia Patients with Poor Prognosis Before Treatment with Second-Generation TKIs.. <i>Blood</i> , 2010, 116, 3409-3409.	0.6	2
231	Skin Toxicity of Hydroxyurea In Ph- Myeloproliferative Neoplasms: Incidence and Clinical Features. <i>Blood</i> , 2010, 116, 3077-3077.	0.6	0
232	Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q). <i>Blood</i> , 2010, 116, 2927-2927.	0.6	0
233	A Retrospective Epidemiological Analysis of 1572 Cases of Ph1- Myeloproliferative Neoplasms (MPNs) From 9 Centers In the Latium: Preliminary Results. <i>Blood</i> , 2010, 116, 5065-5065.	0.6	0
234	Imatinib In Very Elderly CML Patients: What Can We Achieve?.. <i>Blood</i> , 2010, 116, 1229-1229.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. <i>American Journal of Hematology</i> , 2009, 84, 636-640.	2.0	75
236	Comorbidities and FLT3&#x2013;ITD abnormalities as independent prognostic indicators of survival in Elderly acute myeloid leukaemia patients. <i>Hematological Oncology</i> , 2009, 27, 148-153.	0.8	38
237	Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results. <i>International Journal of Hematology</i> , 2009, 90, 486-491.	0.7	2
238	Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal. <i>Leukemia Research</i> , 2009, 33, 391-394.	0.4	6
239	Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations. <i>Leukemia Research</i> , 2009, 33, e134-e136.	0.4	14
240	ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED &gt; 70 Years.. <i>Blood</i> , 2009, 114, 4160-4160.	0.6	0
241	The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients.. <i>Blood</i> , 2009, 114, 1124-1124.	0.6	0
242	Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia: How Important is the Achievement of Complete Cytogenetic Response after 3 Months?. <i>Blood</i> , 2009, 114, 4271-4271.	0.6	0
243	Clinical Usefulness and Safety of Peripherally-Inserted Central Catethers (PICC) in Hematological Patients.. <i>Blood</i> , 2009, 114, 4545-4545.	0.6	0
244	Clinical Results in Patients with Primary and Secondary Myelofibrosis Treated with Monthly Cycles of Oral Melphalan.. <i>Blood</i> , 2009, 114, 4985-4985.	0.6	0
245	Gene Expression Changes in Bone Marrow of MDS Patients with Del(5q) During Lenalidomide Treatment.. <i>Blood</i> , 2009, 114, 2622-2622.	0.6	0
246	Lenalidomide for the Treatment of Low- and Int-1-Risk MDS with Del(5q): Efficacy and Quality of Life Study.. <i>Blood</i> , 2009, 114, 2763-2763.	0.6	1
247	Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged &gt; 60 Years Resistant/Intolerant to Imatinib.. <i>Blood</i> , 2009, 114, 2211-2211.	0.6	0
248	Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).. <i>Blood</i> , 2009, 114, 1777-1777.	0.6	0
249	Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 European Leukemia Net (ELN) Criteria.. <i>Blood</i> , 2009, 114, 3302-3302.	0.6	1
250	Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in a very high complete molecular response rate. <i>Leukemia Research</i> , 2008, 32, 255-261.	0.4	13
251	Ocular side effects in chronic myeloid leukemia patients treated with imatinib. <i>Leukemia Research</i> , 2008, 32, 1022-1025.	0.4	45
252	Pregnancy in patients with myelodysplastic syndromes (MDS). <i>Leukemia Research</i> , 2008, 32, 1605-1607.	0.4	6

#	ARTICLE	IF	CITATIONS
253	Liposomal daunorubicin <i>versus</i> standard daunorubicin: long term followâ€up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60â€years with acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 2008, 143, 681-689.	1.2	54
254	Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2008, 49, 994-997.	0.6	8
255	Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 2328-2332.	0.6	14
256	Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes. <i>Acta Haematologica</i> , 2008, 120, 104-107.	0.7	18
257	Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin. <i>Haematologica</i> , 2008, 93, 1918-1920.	1.7	17
258	Circulating MUC1 Levels (CA15.3) in Myeloproliferative Disorders (MPD). <i>Blood</i> , 2008, 112, 5237-5237.	0.6	1
259	Dasatinib in the Treatment of CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib. <i>Blood</i> , 2008, 112, 4253-4253.	0.6	0
260	Cytoreductive Combined Therapy in Essential Thrombocythemia Patients: Report of the Registro Italiano Trombocitemia (RIT). <i>Blood</i> , 2008, 112, 5243-5243.	0.6	0
261	Cytoreductive Therapeutic Approach in the Essential Thrombocythemia (ET) Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Data. <i>Blood</i> , 2008, 112, 5248-5248.	0.6	0
262	Quality of Life Scores Have a Prognostic Significance In Elderly AML Patients.. <i>Blood</i> , 2008, 112, 1949-1949.	0.6	1
263	Differences in Haematological and Non Haematological Toxicity during Treatment with Imatinib in Early and Late Chronic Phase Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2008, 112, 4281-4281.	0.6	1
264	Prognostic Relevance of Retrospective WHO Re-Classification in 650 MDS Patients Diagnosed by FAB Criteria. <i>Blood</i> , 2008, 112, 5097-5097.	0.6	0
265	Comorbidities and FLT3 Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukemia Patients. <i>Blood</i> , 2008, 112, 3983-3983.	0.6	0
266	Refractory Anaemia with Excess of Blasts in Transformation Re-Evaluated with the WHO Criteria: Identification of Subgroups with Different Survival. <i>Acta Haematologica</i> , 2007, 117, 221-225.	0.7	3
267	Late Relapses in Acute Promyelocytic Leukaemia. <i>Acta Haematologica</i> , 2007, 117, 106-108.	0.7	17
268	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. <i>Haematologica</i> , 2007, 92, 101-105.	1.7	57
269	Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. <i>Leukemia Research</i> , 2007, 31, 1770-1772.	0.4	58
270	Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. <i>Leukemia</i> , 2007, 21, 79-83.	3.3	108



#	ARTICLE	IF	CITATIONS
271	Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia. <i>Annals of Hematology</i> , 2007, 86, 263-270.	0.8	21
272	JAK2 (V617F) Mutation Levels and Marrow Fibrosis in Patients Affected by Budd-Chiari Syndrome and Non-Cirrhotic Extra-Hepatic Portal Vein Obstruction.. <i>Blood</i> , 2007, 110, 4652-4652.	0.6	0
273	Changes in Gene Expression Profiles during Treatment with Erythropoetic Growth Factors in Myelodysplastic Syndromes.. <i>Blood</i> , 2007, 110, 4609-4609.	0.6	0
274	Favourable Outcome of Pregnancy in Essential Thrombocythemia (ET) Patients Treated with Interferon Alpha. A Report from the Registro Italiano Trombocitemia (RIT).. <i>Blood</i> , 2007, 110, 2549-2549.	0.6	0
275	Decisional Flow with a Score System To Start Platelet-Lowering Treatment in Patients with Essential Thrombocythemia (ET): Long-Term Results.. <i>Blood</i> , 2007, 110, 4636-4636.	0.6	0
276	Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2006, 30, 178-182.	0.4	17
277	Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. <i>Annals of Oncology</i> , 2006, 17, 281-285.	0.6	30
278	Long Term Follow-Up of the Gimema GSI 103 AMLE Randomized Trial: Daunoxome Seems To Improve Disease-Free Survival (DFS) of Elderly Patients with Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2006, 108, 1979-1979.	0.6	10
279	Risk Factors for Cardiovascular Events in Myeloproliferative Syndromes.. <i>Blood</i> , 2006, 108, 3595-3595.	0.6	0
280	Quality of Life in Elderly Patients with Acute Myeloid Leukemia.. <i>Blood</i> , 2006, 108, 3320-3320.	0.6	0
281	Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party.. <i>Blood</i> , 2006, 108, 4805-4805.	0.6	0
282	Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.. <i>Blood</i> , 2006, 108, 2158-2158.	0.6	0
283	Darbepoetin for the Treatment of Anemia of Myelodysplastic Syndromes: Efficacy and Improvements in Quality of Life.. <i>Blood</i> , 2006, 108, 2667-2667.	0.6	1
284	Identification of risk factors in atypical chronic myeloid leukemia. <i>Haematologica</i> , 2006, 91, 1566-8.	1.7	78
285	Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation. <i>Leukemia Research</i> , 2005, 29, 33-39.	0.4	11
286	Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. <i>Leukemia Research</i> , 2005, 29, 287-291.	0.4	20
287	Myelodysplastic syndromes in patients under 50 years old: a single institution experience. <i>Leukemia Research</i> , 2005, 29, 749-754.	0.4	23
288	BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results. <i>Bone Marrow Transplantation</i> , 2005, 36, 83-84.	1.3	7

#	ARTICLE	IF	CITATIONS
289	Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. <i>European Journal of Haematology</i> , 2005, 74, 89-90.	1.1	44
290	Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. <i>European Journal of Haematology</i> , 2005, 74, 121-123.	1.1	62
291	Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. <i>Annals of Hematology</i> , 2005, 84, 167-176.	0.8	105
292	PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study.. <i>Blood</i> , 2005, 106, 2600-2600.	0.6	5
293	Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results.. <i>Blood</i> , 2005, 106, 4962-4962.	0.6	1
294	Therapy-Related Myelodysplastic Syndrome (sMDS) /Acute Myelogenous Leukemia (sAML) in Acute Promyelocytic Leukemia (APL) Patients with Long-Lasting Molecular Remission: The GIMEMA Experience.. <i>Blood</i> , 2005, 106, 884-884.	0.6	0
295	Long-Term Results of the GIMEMA LAP AIDA 0493 Amended Protocol in Elderly Patients with Acute Promyelocytic Leukemia (APL).. <i>Blood</i> , 2005, 106, 885-885.	0.6	1
296	Increased Risk of Thrombotic Events in Patients with Acute Promyelocytic Leukemia (APL) Receiving ATRA Treatment: Does It Correlate with CD2 and FLT3 Expression?.. <i>Blood</i> , 2005, 106, 887-887.	0.6	0
297	Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia. <i>Leukemia</i> , 2004, 18, 182-182.	3.3	17
298	Apoptosis Susceptibility and Cell-Cycle Distribution in Cells from Myelodysplastic Syndrome Patients: Modulatory In-Vitro Effects of G-CSF and Interferon- $\gamma$ . <i>Leukemia and Lymphoma</i> , 2004, 45, 1437-1443.	0.6	2
299	Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results.. <i>Blood</i> , 2004, 104, 1523-1523.	0.6	4
300	Association of Hydroxyurea to Imatinib Is Effective in Patients with Chronic Myelogenous Leukemia Resistant to Imatinib Alone.. <i>Blood</i> , 2004, 104, 4693-4693.	0.6	1
301	Survival of elderly patients with acute myeloid leukemia. <i>Haematologica</i> , 2004, 89, 296-302.	1.7	43
302	Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. <i>Haematologica</i> , 2004, 89, 615-7.	1.7	13
303	Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution. <i>Haematologica</i> , 2004, 89, 866-8.	1.7	24
304	A long-term study of young patients with essential thrombocythemia treated with anagrelide. <i>Haematologica</i> , 2004, 89, 1306-13.	1.7	44
305	High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias. <i>Annals of Hematology</i> , 2003, 82, 476-480.	0.8	11
306	Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen. <i>Leukemia</i> , 2003, 17, 925-930.	3.3	38

#	ARTICLE	IF	CITATIONS
307	Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. <i>Leukemia</i> , 2003, 17, 1085-1090.	3.3	74
308	Intracardiac Thrombus in a Patient with Autoimmune Hemolytic Anemia Leading to a Diagnosis of Antiphospholipid Syndrome. <i>Acta Haematologica</i> , 2002, 107, 170-172.	0.7	3
309	Therapy-related myelodysplastic syndrome→acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. <i>Blood</i> , 2002, 99, 822-824.	0.6	125
310	Negative prognostic value of glutathione S-transferase(GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. <i>Blood</i> , 2002, 100, 2703-2707.	0.6	110
311	Elevated expression of IL-3R± in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. <i>Blood</i> , 2002, 100, 2980-2988.	0.6	272
312	Conservative treatment for patients over 80 years with acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2002, 71, 256-259.	2.0	13
313	Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2002, 116, 576-581.	1.2	80
314	Intraventricular thrombosis during all-trans retinoic acid treatment in acute promyelocytic leukemia. <i>Leukemia</i> , 2001, 15, 1311-1313.	3.3	22
315	Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission. <i>Haematologica</i> , 2001, 86, 814-20.	1.7	17
316	Spontaneous remission in adult patients with de novo myelodysplastic syndrome: a possible event. <i>Haematologica</i> , 2001, 86, 1277-80.	1.7	12
317	Molecular and cytogenetic remission in a case of subtype M4E acute myelogenous leukemia with minimal monochemotherapy: high sensitivity or spontaneous remission?. <i>European Journal of Haematology</i> , 2000, 65, 203-206.	1.1	7
318	Treatment of long-lasting priapism in chronic myeloid leukemia at onset. <i>Annals of Hematology</i> , 2000, 79, 644-645.	0.8	24
319	Acute Myeloblastic Leukemia Secondary to Myelodysplasia (MDS-AML): A Comparison of Remission Induction with Three Drugs Versus Standard Two-Drugs Induction. <i>Leukemia and Lymphoma</i> , 2000, 36, 539-541.	0.6	2
320	Granulocytic Sarcoma with Breast and Skin Presentation: A Report of a Case Successfully Treated by Local Radiation and Systemic Chemotherapy. <i>Acta Haematologica</i> , 2000, 104, 34-37.	0.7	16
321	A case-control study of the effects of hydroxyurea on circulating cortisol levels in patients with acute myelogenous leukemia and chronic myeloproliferative disorders. <i>Pharmacological Research</i> , 2000, 42, 389-392.	3.1	1
322	Coranaric thrombotic events in acute promyelocytic leukemia during all-trans retinoic acid treatment: a role for adhesion molecules over expression?. <i>Leukemia</i> , 1999, 13, 312-313.	3.3	10
323	Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy. <i>Leukemia</i> , 1999, 13, 514-517.	3.3	17
324	Acute myeloid leukemia in the elderly: →per aspera ad astra→™?. <i>Leukemia Research</i> , 1999, 23, 603-613.	0.4	19

#	ARTICLE	IF	CITATIONS
325	Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit. <i>Haematologica</i> , 1999, 84, 814-9.	1.7	25
326	Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971â€“1991). <i>Leukemia</i> , 1998, 12, 869-874.	3.3	35
327	Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. , 1998, 58, 105-109.		112
328	Cytotoxic effectors activated by low-dose IL-2 plus IL-12 lyse IL-2-resistant autologous acute myeloid leukaemia blasts. <i>British Journal of Haematology</i> , 1998, 101, 150-157.	1.2	16
329	Etoposide, intermediate-dose cytarabine and carboplatin (VAC): A combination therapy for the blastic phase of chronic myelogenous leukemia. <i>Annals of Oncology</i> , 1997, 8, 175-179.	0.6	11
330	The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged >60 years. <i>Annals of Oncology</i> , 1997, 8, 1273-1275.	0.6	25
331	Management of infective complications in patients with advanced hematologic malignancies in home care. <i>Leukemia</i> , 1997, 11, 1807-1812.	3.3	26
332	64 Myelodysplastic syndromes (MDS) in patients aged >20 and <40 years. <i>Leukemia Research</i> , 1997, 21, S17.	0.4	0
333	Prolonged low doses of oral etoposide may be effective in individual patients with advanced lymphoproliferative disorders refractory to aggressive chemotherapy. <i>Haematologica</i> , 1997, 82, 126-7.	1.7	0
334	Treatment of highâ€“risk myelodysplastic syndromes with lymphoblastoid alpha interferon. <i>British Journal of Haematology</i> , 1996, 95, 364-367.	1.2	9
335	Simultaneous Occurrence of Large B-Cell non-Hodgkin Lymphoma and Myelodysplastic Syndrome Rapidly Evolving into Acute Myeloblastic Leukemia. <i>Leukemia and Lymphoma</i> , 1996, 21, 339-341.	0.6	5
336	Erythropoietin in myelodysplastic syndromes: durable response in a young patient. <i>Haematologica</i> , 1996, 81, 381-2.	1.7	0
337	Is aggressive chemotherapy the best choice for patients with acute nonlymphocytic leukemia after myelodysplastic syndromes?. <i>Leukemia Research</i> , 1995, 19, 213-217.	0.4	3
338	MEC (Mitoxantrone, Etoposide and Intermediate Dose Cytarabine): An Effective Induction Regimen for Previously Untreated Acute Non-Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 1995, 19, 447-451.	0.6	8
339	Polycythaemia vera and cerebral blood flow: a preliminary study with transcranial Doppler. <i>Journal of Internal Medicine</i> , 1993, 234, 599-602.	2.7	16
340	Is Recombinant Human Erythropoietin Treatment in Myelodysplastic Syndromes Worthwhile?. <i>Leukemia and Lymphoma</i> , 1993, 9, 79-83.	0.6	19
341	Bisantrene in Relapsed and Refractory Acute Myelogenous Leukemia. <i>Leukemia and Lymphoma</i> , 1993, 9, 217-220.	0.6	3
342	Erythropoietin treatment of idiopathic myelofibrosis. <i>Haematologica</i> , 1993, 78, 371-3.	1.7	12

#	ARTICLE	IF	CITATIONS
343	Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report. <i>Haematologica</i> , 1993, 78, 123-6.	1.7	4
344	Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia. <i>Leukemia</i> , 1993, 7, 549-52.	3.3	46
345	A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, 750-755.	0.9	92
346	Thymopentin in the Treatment of Myelodysplastic Syndromes. <i>Acta Haematologica</i> , 1991, 86, 115-115.	0.7	1
347	Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. <i>British Journal of Haematology</i> , 1990, 75, 4-9.	1.2	182
348	High doses of ara-C and m-AMSA in the treatment of refractory acute non lymphocytic leukemia. <i>Haematologica</i> , 1990, 75, 249-51.	1.7	4
349	CD 7 positive acute myeloid leukaemia: a subtype associated with cell immaturity. <i>British Journal of Haematology</i> , 1989, 73, 480-485.	1.2	103
350	Immunophenotyping of acute myeloid leukaemia: Relevance of analysing different lineage-associated markers. <i>Blut</i> , 1989, 58, 235-240.	1.2	27
351	Acute nonlymphocytic leukemia in the elderly: results of a retrospective study. <i>Haematologica</i> , 1989, 74, 167-71.	1.7	7